首页> 美国卫生研究院文献>Journal of Toxicologic Pathology >Promotion of liver and kidney carcinogenesis by ethyl tertiary-butyl ether (ETBE) in male Wistar rats
【2h】

Promotion of liver and kidney carcinogenesis by ethyl tertiary-butyl ether (ETBE) in male Wistar rats

机译:乙基叔丁基醚(ETBE)促进雄性Wistar大鼠肝肾癌发生

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tumor-promoting effects of ethyl tertiary-butyl ether (ETBE) were investigated in a 2-stage carcinogenesis bioassay with regard to hepatic and renal carcinogenesis in rats. Male 6-week-old Wistar rats were given drinking water containing N-ethyl-N-(2-hydroxyethyl)nitrosamine (EHEN), as an initiator, at a dose of 500 ppm for 2 weeks. Starting one week thereafter, the animals were administered ETBE at dose levels of 0 (control), 100, 300, 500 or 1,000 mg/kg/day by gavage for 19 weeks from week 4 to 22. Necropsy of all rats was performed at week 23, and livers and kidneys were examined histopathologically. Incidences of hepatocellular adenomas, and those of combined hepatocellular adenomas and carcinomas were significantly elevated in rats given 1,000 mg/kg/day ETBE, but not 100‒500 mg/kg/day ETBE, and there was a significant increase in the average numbers of lesions. No significant differences in incidences and average numbers of renal tubule neoplasms were found in rats administered 100‒1,000 mg/kg/day ETBE. However, the average numbers of atypical tubule hyperplasias, considered to be preneoplastic lesions, were significantly increased in rats given ETBE at 1,000 mg/kg/day, but not in rats given 500 mg/kg/day or lower doses. Thus, these results imply that ETBE has hepatic and renal tumor-promoting activities that affect EHEN-induced carcinogenesis in male rats, and the no-observed-effect level is 500 mg/kg/day under the present experimental conditions.
机译:关于大鼠肝脏和肾脏的癌变,在2期癌变生物测定中研究了乙基叔丁基醚(ETBE)的促肿瘤作用。雄性6周大的Wistar大鼠以500 ppm的剂量接受含有N-乙基-N-(2-羟乙基)亚硝胺(EHEN)作为引发剂的饮用水,持续2周。此后一周开始,从第4周到第22周,通过管饲法以0(对照),100、300、500或1,000 mg / kg /天的剂量水平向动物给药ETBE,持续19周。 23,肝脏和肾脏进行了组织病理学检查。给予ETBE 1,000 mg / kg / day ETBE的大鼠肝细胞腺瘤的发生率以及合并的肝细胞腺瘤和癌的发生率显着升高,但没有100‒500 mg / kg / day ETBE的大鼠发生率显着升高,病变。给予100BE1,000 mg / kg /天ETBE的大鼠,肾小管肿瘤的发生率和平均数量无明显差异。然而,被认为是肿瘤前病变的非典型肾小管增生的平均数目在以ETBE 1,000 mg / kg / day服用的大鼠中明显增加,但在以500 mg / kg / day或更低剂量服用的大鼠中则没有。因此,这些结果表明ETBE具有影响肝和肾肿瘤的活性,这些活性影响EHEN诱导的雄性大鼠的癌变,在目前的实验条件下,未观察到的作用水平为500mg / kg /天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号